Genmab AS (GEN):製薬・医療:M&Aディール及び事業提携情報

◆英語タイトル:Genmab AS (GEN) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA904C9942
◆発行会社(調査会社):GlobalData
◆発行日:2018年11月
◆ページ数:60
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:デンマーク
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥74,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥111,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
Genmab A/S (Genmab) is a biotechnology company that develops differentiated human antibody therapeutics for the treatment of cancer. The company’s marketed antibody, ofatumumab (Arzerra) and Daratumumab (Darzalex) are indicated for the treatment of chronic lymphocytic leukemia and multiple myeloma respectively. Genmab’s products are based on three next generation antibody technologies, namely, HexaBody, DuoBody, and antibody drug conjugate (ADC) technologies. The company works in partnership with various pharmaceutical and biotechnology companies for the co-development and commercialization of antibody-based products. It operates in Denmark, the Netherlands, and the US. Genmab is headquartered in Copenhagen, Denmark.

Genmab AS (GEN) – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 5
List of Figures 5
Genmab A/S, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Genmab A/S, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
Genmab A/S, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Genmab A/S, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9
Genmab A/S, Medical Devices Deals, 2012 to YTD 2018 10
Genmab A/S, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 11
Genmab A/S, Pharmaceuticals & Healthcare, Deal Details 13
Asset Purchase 13
Genmab Acquires Antibody Assets from iDD Biotech 13
Partnerships 14
Mabimmune and Genmab Enter into Research Collaboration 14
Genmab Enters into Co-Development Agreement with BioNTech 15
BioNovion Enters into Agreement with Genmab to Discover and Develop Multiple Bispecific Antibody Products 16
Genmab Enters into Research Agreement with Seattle Genetics 17
Ventana Medical Systems Enters Into Co-Development Agreement With Genmab 18
MAB Discovery Enters into Research Agreement with Genmab for Therapeutic Antibody Products 19
Genmab Enters Into Co-Development Agreement With ADC Therapeutics 20
Genmab Enters into Co-Development Agreement with ADC Therapeutics 21
Genmab Enters Into Agreement With Kyowa Hakko Kirin For Bispecific Antibodies 22
Licensing Agreements 23
Genmab Enters into Licensing Agreement with Immatics Biotechnologies 23
Genmab Enters into Licensing Agreement with Gilead Sciences 24
Novo Nordisk Expands Licensing Agreement with Genmab 25
Genmab Enters into Licensing Agreement with Bristol-Myers Squibb 26
Genmab Enters into Licensing Agreement with Janssen Biotech for Daratumumab 27
Genmab Expands Licensing Agreement With Janssen Biotech 29
Genmab Enters into Licensing Agreement with Janssen Biotech for DuoBody Technology 30
Genmab Enters Into Licensing Agreement With Cormorant Pharma For HuMax-IL8 31
Open Monoclonal Technology Enters into Licensing Agreement with Genmab for OmniRat, OmniMouse and OmniFlic 32
Equity Offering 33
Genmab Raises USD1.2 Million in Private Placement of Shares up on Exercise of Warrants 33
Genmab to Raise USD4.8 Million in Private Placement of Shares upon Exercise of Warrants 34
Genmab Completes Private Placement of Shares for USD181.3 Million 35
Genmab Completes Private Placement Of Shares For US$2 Million Upon Exercise Of Warrants 36
Genmab Completes Private Placement Of Shares For US$5 Million Upon Exercise Of Warrants 37
Asset Transactions 38
Genmab Sells Brooklyn Park Manufacturing Facility To Baxter Healthcare For US$10 Million 38
Acquisition 39
Meditor European Master Fund Sells Its Stake In Genmab 39
Genmab A/S – Key Competitors 40
Genmab A/S – Key Employees 41
Genmab A/S – Locations And Subsidiaries 42
Head Office 42
Other Locations & Subsidiaries 42
Recent Developments 43
Financial Announcements 43
May 08, 2018: Genmab: Interim Report First Quarter 2018 43
Feb 21, 2018: Genmab 2017 Annual Report 44
Nov 08, 2017: Genmab Announces Financial Results for the First Nine Months of 2017 46
Aug 09, 2017: Genmab Announces Financial Results for the First Half of 2017 47
May 10, 2017: Genmab Announces Financial Results for the First Quarter of 2017 48
Feb 22, 2017: Genmab 2016 Annual Report 53
Jan 24, 2017: Genmab reports net sales for DARZALEX in 2016 54
Corporate Communications 55
Feb 08, 2017: Genmab Appoints Judith Klimovsky, MD, as Chief Development Officer 55
Product News 56
06/29/2018: HuMax-AXL-ADC Progress Triggers Milestone Payment to Seattle Genetics 56
05/17/2018: Genmab Announces to Present Abstract on CD3xCD20 at 23rd EHA Annual Congress 57
04/20/2017: Genmab To Present Poster Presentations On HuMax-AXL-ADC at 2017 ASCO Annual Meeting 58
Other Significant Developments 59
Dec 11, 2017: Genmab’s 2017 R&D Update 59
Appendix 60
Methodology 60
About GlobalData 60
Contact Us 60
Disclaimer 60

List of Tables
Genmab A/S, Pharmaceuticals & Healthcare, Key Facts, 2017 2
Genmab A/S, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Genmab A/S, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
Genmab A/S, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Genmab A/S, Deals By Therapy Area, 2012 to YTD 2018 9
Genmab A/S, Medical Devices Deals, 2012 to YTD 2018 10
Genmab A/S, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 11
Genmab Acquires Antibody Assets from iDD Biotech 13
Mabimmune and Genmab Enter into Research Collaboration 14
Genmab Enters into Co-Development Agreement with BioNTech 15
BioNovion Enters into Agreement with Genmab to Discover and Develop Multiple Bispecific Antibody Products 16
Genmab Enters into Research Agreement with Seattle Genetics 17
Ventana Medical Systems Enters Into Co-Development Agreement With Genmab 18
MAB Discovery Enters into Research Agreement with Genmab for Therapeutic Antibody Products 19
Genmab Enters Into Co-Development Agreement With ADC Therapeutics 20
Genmab Enters into Co-Development Agreement with ADC Therapeutics 21
Genmab Enters Into Agreement With Kyowa Hakko Kirin For Bispecific Antibodies 22
Genmab Enters into Licensing Agreement with Immatics Biotechnologies 23
Genmab Enters into Licensing Agreement with Gilead Sciences 24
Novo Nordisk Expands Licensing Agreement with Genmab 25
Genmab Enters into Licensing Agreement with Bristol-Myers Squibb 26
Genmab Enters into Licensing Agreement with Janssen Biotech for Daratumumab 27
Genmab Expands Licensing Agreement With Janssen Biotech 29
Genmab Enters into Licensing Agreement with Janssen Biotech for DuoBody Technology 30
Genmab Enters Into Licensing Agreement With Cormorant Pharma For HuMax-IL8 31
Open Monoclonal Technology Enters into Licensing Agreement with Genmab for OmniRat, OmniMouse and OmniFlic 32
Genmab Raises USD1.2 Million in Private Placement of Shares up on Exercise of Warrants 33
Genmab to Raise USD4.8 Million in Private Placement of Shares upon Exercise of Warrants 34
Genmab Completes Private Placement of Shares for USD181.3 Million 35
Genmab Completes Private Placement Of Shares For US$2 Million Upon Exercise Of Warrants 36
Genmab Completes Private Placement Of Shares For US$5 Million Upon Exercise Of Warrants 37
Genmab Sells Brooklyn Park Manufacturing Facility To Baxter Healthcare For US$10 Million 38
Meditor European Master Fund Sells Its Stake In Genmab 39
Genmab A/S, Key Competitors 40
Genmab A/S, Key Employees 41
Genmab A/S, Subsidiaries 42

List of Figures
Genmab A/S, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
Genmab A/S, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
Genmab A/S, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
Genmab A/S, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
Genmab A/S, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Genmab A/S, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 7
Genmab A/S, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Genmab A/S, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9
Genmab A/S, Medical Devices Deals, 2012 to YTD 2018 10

★海外企業調査レポート[Genmab AS (GEN):製薬・医療:M&Aディール及び事業提携情報]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • The Boeing Co (BA):企業の財務・戦略的SWOT分析
    The Boeing Co (BA) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and th …
  • Ajinomoto Co Inc (2802):企業の財務・戦略的SWOT分析
    Ajinomoto Co Inc (2802) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses a …
  • Ally Financial Inc.:企業の戦略・SWOT・財務情報
    Ally Financial Inc. - Strategy, SWOT and Corporate Finance Report Summary Ally Financial Inc. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings a …
  • Maxeda B.V.:企業の戦略・SWOT・財務情報
    Maxeda B.V. - Strategy, SWOT and Corporate Finance Report Summary Maxeda B.V. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate act …
  • Purdue Pharma Canada-製薬・医療分野:企業M&A・提携分析
    Summary Purdue Pharma Canada (Purdue Pharma), a subsidiary of Purdue Pharma L.P., is a research-based pharmaceutical company which focuses on development, manufacturing and commercialization of medicines for patients and healthcare professionals. The company portfolio of products includes laxatives, …
  • Kawasaki Heavy Industries Ltd (7012):企業の財務・戦略的SWOT分析
    Kawasaki Heavy Industries Ltd (7012) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and …
  • Sembcorp Industries Ltd (U96)-エネルギー分野:企業M&A・提携分析
    Summary Sembcorp Industries Limited (Sembcorp) is a diversified energy, water and marine company. The company’s utilities division provides energy and water to industrial and municipal customers. Its energy operations include power generation, steam production and supply and natural gas import suppl …
  • ALS Ltd (ALQ):企業の財務・戦略的SWOT分析
    ALS Ltd (ALQ) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the pot …
  • Santa Fe Group A/S:企業の戦略・SWOT・財務情報
    Santa Fe Group A/S - Strategy, SWOT and Corporate Finance Report Summary Santa Fe Group A/S - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and …
  • Laboratoire Aguettant SA:製薬・医療:M&Aディール及び事業提携情報
    Summary Laboratoire Aguettant SA (Aguettant) is a pharmaceutical company that that focuses on the development, manufacturing and commercialisation of injectable hospital medicines. The company offers sterile injectable medicines in various dosages and pharmaceutical forms. It provides its products f …
  • Asda Stores Ltd:企業の戦略・SWOT・財務情報
    Asda Stores Ltd - Strategy, SWOT and Corporate Finance Report Summary Asda Stores Ltd - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corpo …
  • Diagnostica Stago Inc:企業の製品パイプライン分析2018
    Summary Diagnostica Stago Inc (Stago), a subsidiary of Diagnostica Stago SAS, is a medical device company that develops and distributes in-vitro diagnostic products. The company develops coagulation automation systems. It provides products such as hemostasis analyzers, viscosity based detection syst …
  • Electromagnetic Geoservices ASA (EMGS):企業の財務・戦略的SWOT分析
    Summary Electromagnetic Geoservices ASA (EMGS) is an oil and gas service provider that explores workflow working with seismic, petrophysical and geologic data. The company gathers controlled source electromagnetic data and conduct modeling, integration, interpretation. Its technology finds applicati …
  • Abbott Diabetes Care Inc-医療機器分野:企業M&A・提携分析
    Summary Abbott Diabetes Care Inc (ADC), formerly TheraSense Inc, a subsidiary of Abbott Laboratories, is a medical device company that discovers, develops, manufactures, and markets pharmaceuticals and medical products for personal use and hospital use. The company’s products include glucose monitor …
  • Daewoo Shipbuilding & Marine Engineering Co Ltd:戦略・SWOT・企業財務分析
    Daewoo Shipbuilding & Marine Engineering Co Ltd - Strategy, SWOT and Corporate Finance Report Summary Daewoo Shipbuilding & Marine Engineering Co Ltd - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, o …
  • Wingstop Inc.:企業の戦略・SWOT・財務情報
    Wingstop Inc. - Strategy, SWOT and Corporate Finance Report Summary Wingstop Inc. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate …
  • Calimmune Inc:製薬・医療:M&Aディール及び事業提携情報
    Summary Calimmune Inc (Calimmune), a subsidiary of CSL Behring Australia Pty Ltd, is a novel gene therapy program developer. The company’s ex vivio autulogus cell therapy includes CAL-1 and CAL-H. Its CAL-1 offers cell therapies for HIV AIDS. Calimmune’s CAL-H cell therapy provides himoglobinopathie …
  • Unilever Pakistan Limited:企業の戦略・SWOT・財務情報
    Unilever Pakistan Limited - Strategy, SWOT and Corporate Finance Report Summary Unilever Pakistan Limited - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service …
  • Japan Tobacco Inc.:企業の戦略・SWOT・財務分析
    Japan Tobacco Inc. - Strategy, SWOT and Corporate Finance Report Summary Japan Tobacco Inc. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and …
  • GOBARTO S.A.:企業の戦略・SWOT・財務分析
    GOBARTO S.A. - Strategy, SWOT and Corporate Finance Report Summary GOBARTO S.A. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate a …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆